Continuous subcutaneous insulin infusion (CSII) reduced hemoglobin A1c levels by 1.8% and decreased hospitalizations in a study of T1DM patients with gastroparesis, but gastric symptoms were not assessed [17]. This evidence concerns the gene INS and gastroparesis.